Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the sale, the chief executive officer now owns 952,892 shares of the company's stock, valued at $21,135,144.56. The trade was a 1.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, June 3rd, Samuel Kintz sold 7,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.05, for a total value of $150,375.00.
• On Monday, May 19th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.49, for a total value of $82,450.00.
• On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.08, for a total value of $107,026.40.
• On Thursday, April 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.42, for a total value of $82,100.00.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded down $0.27 on Friday, reaching $21.30. The company had a trading volume of 518,501 shares, compared to its average volume of 293,457. The firm has a market capitalization of $1.05 billion, a PE ratio of -11.09 and a beta of 0.79. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The firm has a 50-day moving average of $18.79 and a 200-day moving average of $20.59.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ELVN shares. HC Wainwright boosted their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. The Goldman Sachs Group began coverage on Enliven Therapeutics in a report on Monday, June 16th. They issued a "buy" rating and a $37.00 price target for the company. Jones Trading decreased their price target on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Finally, Robert W. Baird upped their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $39.60.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ELVN. Charles Schwab Investment Management Inc. boosted its stake in shares of Enliven Therapeutics by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock valued at $5,892,000 after buying an additional 6,611 shares during the last quarter. Swiss National Bank boosted its stake in shares of Enliven Therapeutics by 13.9% during the 4th quarter. Swiss National Bank now owns 41,873 shares of the company's stock valued at $942,000 after buying an additional 5,100 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at approximately $367,000. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at approximately $97,000. Finally, Vanguard Group Inc. boosted its stake in shares of Enliven Therapeutics by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock valued at $44,452,000 after buying an additional 55,283 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.